NO20092358L - Krystallinske former GLYT1 - Google Patents

Krystallinske former GLYT1

Info

Publication number
NO20092358L
NO20092358L NO20092358A NO20092358A NO20092358L NO 20092358 L NO20092358 L NO 20092358L NO 20092358 A NO20092358 A NO 20092358A NO 20092358 A NO20092358 A NO 20092358A NO 20092358 L NO20092358 L NO 20092358L
Authority
NO
Norway
Prior art keywords
crystalline forms
glyt1
psychoses
methanone
piperazin
Prior art date
Application number
NO20092358A
Other languages
English (en)
Other versions
NO342150B1 (no
Inventor
Emmanuel Pinard
Andre Gerard Bubendorf
Olaf Grassmann
Franziska E Rohrer
Annette Deynet-Vucenovic
Ralph Diodone
Kai Lindenstruth
Urs Schwitter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38988312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092358(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20092358L publication Critical patent/NO20092358L/no
Publication of NO342150B1 publication Critical patent/NO342150B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår fire distinkte krystallinske former og en amorf form av [4-(3-fluor-5-trifluormetyl-pyridin-2-yl)-piperazin-1-yl]-[5-metansulfonyl-2-((S)-2,2,2-trifluor-1-metyl-etoksy)-fenyl]-metanon og anvendelse av dem ved fremstilling av farmasøytiske preparater. Forbindelsene ifølge oppfinnelsen er egnet for fremstilling av et medikament anvendelige for behandling av psykoser, smerte, nevrodegenerative dysfunksjon i hukommelse og læring, schizofreni, demens og andre sykdommer hvor kognitive prosesser er svekket, så som oppmerksomhetssviktslidelser eller Alzheimers sykdom.
NO20092358A 2006-12-28 2009-06-19 Krystallinsk form A av [4-(3-fluor-5-trifluormetylpyridin-2-yl)-piperazin-1-yl]-[5-metansulfonyl-2-((S)-2,2,2-trifluor-1-metyl-etoksy)-fenyl]-metanon, metode for fremstilling av denne, farmasøytisk preparat omfattende denne samt anvendelse av denne for behandling av sykdom NO342150B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06127269 2006-12-28
PCT/EP2007/064104 WO2008080821A1 (en) 2006-12-28 2007-12-18 Crystalline forms glyt1

Publications (2)

Publication Number Publication Date
NO20092358L true NO20092358L (no) 2009-06-22
NO342150B1 NO342150B1 (no) 2018-04-03

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092358A NO342150B1 (no) 2006-12-28 2009-06-19 Krystallinsk form A av [4-(3-fluor-5-trifluormetylpyridin-2-yl)-piperazin-1-yl]-[5-metansulfonyl-2-((S)-2,2,2-trifluor-1-metyl-etoksy)-fenyl]-metanon, metode for fremstilling av denne, farmasøytisk preparat omfattende denne samt anvendelse av denne for behandling av sykdom

Country Status (33)

Country Link
US (5) US20080214561A1 (no)
EP (1) EP2114405B1 (no)
JP (1) JP4799666B2 (no)
KR (1) KR101130146B1 (no)
CN (1) CN101573114A (no)
AR (1) AR064545A1 (no)
AU (1) AU2007341356B2 (no)
BR (1) BRPI0720829B8 (no)
CA (1) CA2673667A1 (no)
CL (1) CL2007003830A1 (no)
CO (1) CO6190613A2 (no)
CR (1) CR10846A (no)
CY (1) CY1116350T1 (no)
DK (1) DK2114405T3 (no)
EC (1) ECSP099471A (no)
ES (1) ES2535040T3 (no)
HR (1) HRP20150573T1 (no)
HU (1) HUE025032T2 (no)
MA (1) MA31029B1 (no)
MX (1) MX2009006859A (no)
MY (1) MY188367A (no)
NO (1) NO342150B1 (no)
NZ (1) NZ577502A (no)
PE (1) PE20081556A1 (no)
PL (1) PL2114405T3 (no)
PT (1) PT2114405E (no)
RS (1) RS53910B1 (no)
RU (1) RU2463295C2 (no)
SI (1) SI2114405T1 (no)
TW (1) TWI388552B (no)
UA (1) UA100232C2 (no)
WO (1) WO2008080821A1 (no)
ZA (1) ZA200904423B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007341356B2 (en) 2006-12-28 2013-08-29 F. Hoffmann-La Roche Ag Crystalline forms Glyt1
WO2010099323A1 (en) * 2009-02-26 2010-09-02 Thar Pharmaceuticals, Inc. Crystalization of pharmaceutical compounds
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
BR112014028872A2 (pt) * 2012-05-25 2017-06-27 Basf Se forma b cristalina, processo para a produção das formas b e ab, mistura da forma b cristalina, agente de proteção, uso da forma b cristalina e método para o combate do crescimento indesejado dos vegetais
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
AU2021205510A1 (en) 2020-01-09 2022-07-21 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
WO2022014397A1 (ja) * 2020-07-13 2022-01-20 日本碍子株式会社 精製方法
AU2022273051A1 (en) * 2021-05-14 2023-12-07 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
CA3220741A1 (en) * 2021-05-27 2022-12-01 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
ME00116B (me) * 2003-08-11 2010-10-10 Hoffmann La Roche Piperazin sa ili supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1
AU2007341356B2 (en) 2006-12-28 2013-08-29 F. Hoffmann-La Roche Ag Crystalline forms Glyt1

Also Published As

Publication number Publication date
JP2010514725A (ja) 2010-05-06
DK2114405T3 (en) 2015-04-07
ZA200904423B (en) 2010-05-26
PE20081556A1 (es) 2008-11-28
TW200833677A (en) 2008-08-16
TWI388552B (zh) 2013-03-11
EP2114405B1 (en) 2015-03-11
US8039473B2 (en) 2011-10-18
KR20090094166A (ko) 2009-09-03
EP2114405A1 (en) 2009-11-11
ES2535040T3 (es) 2015-05-04
WO2008080821A1 (en) 2008-07-10
ECSP099471A (es) 2009-07-31
CA2673667A1 (en) 2008-07-10
CY1116350T1 (el) 2017-03-15
US20100311971A1 (en) 2010-12-09
HRP20150573T1 (en) 2015-07-03
NO342150B1 (no) 2018-04-03
SI2114405T1 (sl) 2015-06-30
PL2114405T3 (pl) 2015-08-31
NZ577502A (en) 2012-02-24
US20080214561A1 (en) 2008-09-04
AU2007341356A1 (en) 2008-07-10
PT2114405E (pt) 2015-06-02
CL2007003830A1 (es) 2008-07-11
MX2009006859A (es) 2009-07-03
AU2007341356B2 (en) 2013-08-29
CN101573114A (zh) 2009-11-04
MA31029B1 (fr) 2009-12-01
MY188367A (en) 2021-12-06
US20130197225A1 (en) 2013-08-01
US20110295007A1 (en) 2011-12-01
BRPI0720829B8 (pt) 2021-05-25
RU2009124113A (ru) 2011-02-10
HUE025032T2 (en) 2016-02-29
KR101130146B1 (ko) 2012-03-28
JP4799666B2 (ja) 2011-10-26
RS53910B1 (en) 2015-08-31
CO6190613A2 (es) 2010-08-19
BRPI0720829A2 (pt) 2014-02-25
UA100232C2 (uk) 2012-12-10
US20120309969A1 (en) 2012-12-06
CR10846A (es) 2009-08-12
RU2463295C2 (ru) 2012-10-10
BRPI0720829B1 (pt) 2020-04-07
AR064545A1 (es) 2009-04-08

Similar Documents

Publication Publication Date Title
NO20092358L (no) Krystallinske former GLYT1
NO20060768L (no) 1-(2-amino-benzol)-piperazinderivater som glycinopptaks-inhibitorer for behandling av psykoser
TW200700068A (en) Phthalazine, aza-and diaza-phthalazine compounds and methods of use
NO20061363L (no) Pyrazolo- og imidazo- pyrimidinderivater
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
UY30408A1 (es) Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
NO20082481L (no) Nye 2-aminoheterosykluser som er nyttige ved behandling av ABETA-relaterte patologier
MX2012001985A (es) Derivados de 3-amino-5-fenil-5,6-dihidro-2h-[1,4]oxazina.
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NI201300055A (es) Compuestos y su uso como inhibidores de bace
EA200901373A1 (ru) Аминогетероциклические соединения
BRPI0413497B8 (pt) piperazina com ou que substitui grupo fenila, e seu uso e seu processo de preparação, bem como medicamento
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
NO20081843L (no) Farmasoytisk sammensetning for forbedret kognitiv funksjon
MX2013014007A (es) [1,3] oxazinas.
ATE549311T1 (de) Amino-propanolderivative als modulatoren des sphingosin-1-phosphat-rezeptors
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
MX2009006947A (es) Derivados de pirimidona 6-heterociclica 2-sustituida.
TW200602297A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
ES2333026T3 (es) Derivados de ciclohexil-1,4-diamina sustituidos.
NO20075477L (no) Tetrahydro-pyridoazepin-8-one og beslektede forbindelser for behandling av schizofreni
NZ593279A (en) Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors
NO20070665L (no) Derivater av 1-fenylalkankarboksylsyrer for behandlingen av neurodegenerative sykdommer